New drug duo aims to wipe out lingering leukemia cells
NCT ID NCT07264010
Summary
This study is testing whether combining two existing drugs, sorafenib and venetoclax, can help patients with acute myeloid leukemia (AML) who still have tiny, hard-to-detect amounts of cancer left after their first treatment. The goal is to use this drug combination as a 'pre-emptive' therapy to try to prevent the cancer from coming back. Researchers will measure if the treatment safely reduces or eliminates these lingering cancer cells in about 87 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.